DNA vaccines and recombinant allergens with reduced allergenic activity treat allergies

Petrova, Stanislava Yu.; Khlgatian, Svetlana V.; Svirshchevskaya, E. V.; Vasilyeva, Anna V.; Berzhets, V M

doi:10.15275/rusomj.2021.0102

Cited by 1 publication

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genetically modified allergens with reduced immunoglobulin IgE-binding can reduce allergic side effects in immunotherapy. Their therapeutic potential has been demonstrated by their ability to induce IgG-blocking antibodies and to modify Th2-cell-mediated hypersensitivity (Marth et al, 2014;Petrova et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Production of a Ric c3 hypo-allergen with no IgE binding or anaphylactogenic activity

Bartholazzi,

Lodi,

Mello

et al. 2023

Braz. J. Biol.

View full text Add to dashboard Cite

Several studies have been carried out to expand the use of Ricinus communis L. castor bean (Ricinus communis L castor bean.). This oilseed finds appropriate conditions for its development in Brazil, with more than 700 applications. The main allergens of this plant are Ric c1 and Ric c3, that cross-react with various aeroallergens and food allergens such as peanuts, soybeans, corn, and wheat. This study aimed to determine the effect of mutations in Ric c3 amino acid residues known to affect IgE binding and allergy challenges. Based on the Ric c3 structure, B-cell epitopes, and amino acid involved in IgE binding, we produce recombinant mutant protein, mrRic c3, secreted from E. coli. Strategic glutamic acid residues in IgE-biding regions were changed by Leucine. The allergenicity of mrRic c3 was evaluated by determination of IgE, IgG1, and total IgG in immunized Balb/c mice and by degranulation assays of mast cells isolated from Wistar rats. The mrRic c3 presented a percentage of mast cell degranulation close to that seen in the negative control, and the immunization of mice with mrRic c3 presented lower levels of IgE and IgG1 than the group treated with the protein without mutations. The mutant mrRic c3 had an altered structure and reduced ability to stimulate pro-inflammatory responses and bind IgE but retained its ability to induce blocking antibodies. Thus, producing a hypoallergenic mutant allergen (mrRic c3) may be essential in developing new AIT strategies.

show abstract

Section: Introductionmentioning

confidence: 99%